Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

[1]  S. Urban,et al.  New Insights into Hepatitis D Virus Persistence: the Role of Interferon Response and Implications for Upcoming Novel Therapies. , 2020, Journal of hepatology.

[2]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[3]  M. Peppelenbosch,et al.  Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection , 2019, The Journal of infectious diseases.

[4]  M. Buti,et al.  Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. , 2019, Journal of hepatology.

[5]  M. Manns,et al.  Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. , 2019, The Lancet. Infectious diseases.

[6]  H. Goyal,et al.  Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis , 2018, Gut.

[7]  R. Idilman,et al.  Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study , 2018, Hepatology.

[8]  W. Haefeli,et al.  The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics , 2018, Clinical pharmacology and therapeutics.

[9]  A. Lohse,et al.  Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo , 2017, Gut.

[10]  S. Kanner,et al.  RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg , 2017, Science Translational Medicine.

[11]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[12]  R. Idilman,et al.  A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study , 2017 .

[13]  Yan Zhou,et al.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. , 2016, Gastroenterology.

[14]  Y. Ni,et al.  Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options , 2016, Nature Reviews Gastroenterology &Hepatology.

[15]  W. Haefeli,et al.  First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.

[16]  Thorsten Lehr,et al.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. , 2016, Journal of hepatology.

[17]  F. Negro,et al.  The hepatitis delta virus: Replication and pathogenesis. , 2016, Journal of hepatology.

[18]  H. Waterham,et al.  Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype , 2015, Hepatology.

[19]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[20]  M. Manns,et al.  Development and evaluation of a baseline-event-anticipation score for hepatitis delta , 2014, Journal of viral hepatitis.

[21]  U. Haberkorn,et al.  Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts , 2013, Hepatology.

[22]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[23]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[24]  M. Manns,et al.  Peginterferon plus adefovir versus either drug alone for hepatitis delta. , 2011, The New England journal of medicine.

[25]  Y. Ni,et al.  Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction , 2009, Journal of Virology.

[26]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[27]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[28]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.